Condition
Inclusion Body Myositis (IBM)
Total Trials
4
Recruiting
0
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (2)
Trial Status
Completed2
Active Not Recruiting1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02481453Phase 2CompletedPrimary
Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis
NCT06450886Phase 2Active Not RecruitingPrimary
Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
NCT06644482Not ApplicableCompletedPrimary
Exercise as Treatment for Patients With Inclusion Body Myositis
NCT02483845Phase 1UnknownPrimary
Natalizumab in Inclusion Body Myositis (IBM)
Showing all 4 trials